Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98

[11] Corte MD(2017)The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data Clin Cancer Res 23 2702-6140

[12] Vazquez J(2009)Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer Cancer Res 69 6131-287

[13] Junquera S(2009)Design, conduct, and analyses of Breast International Group (BIG) 1–98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer Clin Trials 6 272-2757

[14] Sanchez R(2005)A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747-1108

[15] Alvarez AC(2011)Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up Lancet Oncol 12 1101-3852

[16] Niemeier LA(2007)Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 J Clin Oncol 25 3846-28

[17] Dabbs DJ(2008)Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial Lancet Oncol 9 23-320

[18] Beriwal S(2012)Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers Breast Cancer Res Treat 133 311-675

[19] Striebel JM(2014)Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide Breast Cancer Res 16 R7-1072

[20] Bhargava R(1958)Fluoxymesterone therapy in advanced breast cancer N Engl J Med 259 673-7782

[11] Corte MD(2017)The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data Clin Cancer Res 23 2702-6140

[12] Vazquez J(2009)Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer Cancer Res 69 6131-287

[13] Junquera S(2009)Design, conduct, and analyses of Breast International Group (BIG) 1–98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer Clin Trials 6 272-2757

[14] Sanchez R(2005)A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747-1108

[15] Alvarez AC(2011)Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up Lancet Oncol 12 1101-3852

[16] Niemeier LA(2007)Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 J Clin Oncol 25 3846-28

[17] Dabbs DJ(2008)Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial Lancet Oncol 9 23-320

[18] Beriwal S(2012)Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers Breast Cancer Res Treat 133 311-675

[19] Striebel JM(2014)Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide Breast Cancer Res 16 R7-1072

[20] Bhargava R(1958)Fluoxymesterone therapy in advanced breast cancer N Engl J Med 259 673-7782